GlassScriptPhysician profile
Andrew Carney
NPI 1861921868
$3,135.30
in general payments reported to CMS, 2019-2025
28 companies · $560 in 2025
The $560 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $882 · 2021: $735 · 2022: $153 · 2023: $425 · 2024: $380 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313 · Education: $52.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.12 |
| Education | $52.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $755.14 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $693.16 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $271.54 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.53 | 2020-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $158.27 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $157.00 | 2020-2021 | |
| Amgen INC. | $141.95 | 2021-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $116.25 | 2020-2021 | |
| Pfizer INC. | $100.17 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $64.63 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.88 | 2020 | |
| Allergan, INC. | $44.54 | 2020 | |
| Genentech USA, INC. | $40.44 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $37.43 | 2020 | |
| Phadia US INC. | $36.25 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $31.32 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $30.89 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $27.20 | 2025 | Fanapt |
| Exact Sciences Corporation | $27.13 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $25.88 | 2023 | |
| Esperion Therapeutics, INC. | $20.85 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2024 | |
| Novartis Pharmaceuticals Corporation | $16.97 | 2021 | |
| Astellas Pharma US INC | $16.49 | 2020 | |
| Adlon Therapeutics L.P. | $15.36 | 2020 | |
| Antares Pharma, INC. | $14.58 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.90 | 2021 | |
| Hikma Pharmaceuticals USA | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Carney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.